Background: 30-80% of patients being treated in intensive care units in the perioperative period develop hyperglycemia. This stress hyperglycemia is induced and maintained by inflammatory-endocrine and iatrogenic stimuli and generally requires treatment. There is uncertainty regarding the optimal blood glucose targets for patients with diabetes mellitus.
Methods: This review is based on pertinent publications retrieved by a selective search in PubMed and Google Scholar.
Results: Patients in intensive care with pre-existing diabetes do not benefit from blood sugar reduction to the same extent as metabolically healthy individuals, but they, too, are exposed to a clinically relevant risk of hypoglycemia. A therapeutic range from 4.4 to 6.1 mmol/L (79-110 mg/dL) cannot be justified for patients with diabetes mellitus. The primary therapeutic strategy in the perioperative setting should be to strictly avoid hypoglycemia. Neurotoxic effects and the promotion of wound-healing disturbances are among the adverse consequences of hyperglycemia. Meta-analyses have shown that an upper blood sugar limit of 10 mmol/L (180 mg/dL) is associated with better outcomes for diabetic patients than an upper limit of less than this value. The target range of 7.8-10 mmol/L (140-180 mg/dL) proposed by specialty societies for hospitalized patients with diabetes seems to be the best compromise at present for optimizing clinical outcomes while avoiding hypoglycemia. The method of choice for achieving this goal in intensive care medicine is the continuous intravenous administration of insulin, requirng standardized, high-quality monitoring conditions.
Conclusion: Optimal blood sugar control for diabetic patients in intensive care meets the dual objectives of avoiding hypoglycemia while keeping the blood glucose concentration under 10 mmol/L (180 mg/dL). Nutrition therapy in accordance with the relevant guidelines is an indispensable pre - requisite.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8715312 | PMC |
http://dx.doi.org/10.3238/arztebl.m2021.0221 | DOI Listing |
Chin J Integr Med
January 2025
Department of Ultrasound in Medicine, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, 310009, China.
Objective: To evaluate the therapeutic effects of Kuanxiong Aerosol (KXA) on ischemic stroke with reperfusion and elucidate the underlying pharmacological mechanisms.
Methods: In vivo pharmacological effects on ischemic stroke with reperfusion was evaluated using the transient middle cerebral artery occlusion (t-MCAO) mice model. To evaluate short-term outcome, 30 mice were randomly divided into vehicle group (n=15) and KXA group (n=15).
Langenbecks Arch Surg
January 2025
Department of Surgery, Division of HBP Surgery & Liver Transplantation, Korea University College of Medicine, Seoul, Korea.
Purpose: Pancreatectomy patients often experience challenging fluctuations in blood glucose levels; therefore, they require a reliable monitoring system. This study aimed to determine the accuracy and acceptability of a continuous glucose monitoring (CGM) system compared with the intermittent capillary glucose test in patients who have undergone pancreatectomy.
Methods: Thirty non-diabetic pancreatectomy patients participated.
Eur J Heart Fail
January 2025
School of Cardiovascular and Metabolic Health, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Aims: A cardiovascular magnetic resonance (CMR) approach to non-invasively estimate left ventricular (LV) filling pressure was recently developed and shown to correlate with invasively measured pulmonary capillary wedge pressure (PCWP). We examined the association between CMR-estimated PCWP (CMR-PCWP) and other imaging and biomarker measures of congestion, and the effect of empagliflozin on these, in the SUGAR-DM-HF trial (NCT03485092).
Methods And Results: SUGAR-DM-HF enrolled 105 patients with heart failure with reduced ejection fraction (HFrEF) and pre-diabetes or type 2 diabetes who were randomly assigned to empagliflozin 10 mg or placebo once daily for 36 weeks.
Vet Med Sci
January 2025
Department of Statistics, Faculty of Science, University of Muğla Sıtkı Koçman, Muğla, Turkey.
Background: There is a lack of data on the validation and diagnostic performance of the Freestyle Optium Neo-H (Freestyle) and Centrivet GK (Centrivet) devices for the diagnosis of hypoglycaemia, hyperglycaemia and hyperketonaemia in goats.
Objectives: The aim of the present study was to validate the Freestyle and Centrivet for the analysis of whole blood beta-hydroxybutyric acid (BHBA) and to validate the Freestyle for the analysis of whole blood glucose concentrations using the reference method (RM) in goat blood collected from the jugular and ear veins.
Methods: Venous blood samples were utilised to assess glucose and BHBA concentrations using the Freestyle, Centrivet and RM.
Nanomaterials (Basel)
December 2024
Guangdong Provincial Key Laboratory of Electronic Functional Materials and Devices, Huizhou University, Huizhou 516001, China.
Non-enzymatic glucose detection is an effective strategy to control the blood glucose level of diabetic patients. A novel hierarchical core-shell structure of nickel hydroxide shell coated copper hydroxide core based on copper foam (Ni(OH)@Cu(OH)-CF) was fabricated and derived from NiO@CuO-CF for glucose sensing. Cyclic voltammetry and amperometry experiments have demonstrated the efficient electrochemical catalysis of glucose under alkaline conditions.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!